Singleton Hospital

Running trials

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Recruiting

  Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

  NCT06985706· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Active, not recruiting

  CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Source

• Recruiting

  A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT05254743· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Source

• Active, not recruiting

  Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04546620· Phase 2· Source

• Active, not recruiting

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· Phase 3· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· Source

• Recruiting

  Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

  NCT04050345· Source

• Recruiting

  Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

  NCT03150576· Phase 2/3· Source

• Active, not recruiting

  Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

  NCT02804815· Phase 3· Source

• Active, not recruiting

  CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

  NCT04116047· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia2 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Diabetic eye disease1 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Verapamil SR in Adults With Type 1 Diabetes

  NCT04545151· Phase 2· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

  NCT03173560· Phase 2· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Source